Related Experiment Videos
[Schizophrenia, affective symptoms and clozapine]
J A Meynard1, R Bernadet, M F Sanchez
1Chef se service, CHS, La Rochelle.
L'Encephale
|June 1, 1995
Summary
Clozapine effectively treats treatment-resistant schizophrenia and related psychotic disorders. This study found similar response rates in chronic schizophrenic and mixed-patient groups, suggesting clozapine
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Context:
- Clozapine is an established treatment for schizophrenia.
- Treatment resistance is a significant challenge in managing severe psychiatric disorders.
- Limited data exists on clozapine's efficacy in mixed psychotic populations.
Purpose:
- To compare clozapine's effectiveness in chronic schizophrenic (CS) patients versus mixed patients (MP) with major affective disorders or schizoaffective disorders.
- To evaluate treatment response based on symptom reduction, relapse rates, social functioning, and quality of life.
Summary:
- Nineteen treatment-resistant patients (5 CS, 14 MP) received clozapine (400-800 mg/day) for 12-38 months.
- Significant symptom improvement was observed in 60% of CS and 70% of MP.
- Response rates were comparable between groups, with younger, less chronically ill MP patients showing higher response scores.
Impact:
- Clozapine demonstrates broad efficacy across different severe psychotic disorders.
- Findings support clozapine's use in treatment-resistant major affective disorders and schizoaffective disorders.
- Early intervention in younger patients may optimize clozapine treatment outcomes.